H. Lundbeck A/S has received marketing authorisation from South Korea’s Ministry of Food and Drug Safety (MFDS) for Vyepti (eptinezumab) as a preventive treatment for migraine in adults.

• Clinical basis: The approval was supported by data from multiple Phase 3 studies, including the SUNRISE trial conducted in a predominantly Asian population with chronic migraine.
• Mechanism and route: Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) humanised monoclonal antibody developed for intravenous administration.
• Target indication: Intended for the preventive treatment of migraine in adults experiencing recurrent migraine attacks.

This summary is based on a press release issued by H. Lundbeck A/S via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.